Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M4CxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\VeWlEPTB;MD62NVI{PyEQvF2= M3y2SXNCVkeHUh?=
H4 M2OxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm5W4RKSzVyPUCuOlYzQCEQvF2= MnHaV2FPT0WU
PA-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrvNWZKSzVyPUCuPFcxQTZizszN NUi3XWIxW0GQR1XS
NKM-1 NGr5SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfiTWM2OD1zLkC0PVMyKM7:TR?= MkjrV2FPT0WU
NEC8 M1XBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES4TlNKSzVyPUGuNlE2PzJizszN M4H5[HNCVkeHUh?=
EoL-1-cell NYnX[2xIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1La[GlEPTB;MT6yOlcxOSEQvF2= MmTSV2FPT0WU
K5 M2PPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTTfnhKSzVyPUGuOFIxPzJizszN MmHuV2FPT0WU
QIMR-WIL NETuXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC3PIpwUUN3ME2xMlYxQDV2IN88US=> NEfsdWlUSU6JRWK=
MOLT-16 NFHNXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwN{i2NFQh|ryP NFjMfYRUSU6JRWK=
CHP-212 NH3yWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LmTWlEPTB;MT64NVM3QSEQvF2= NHjMU3NUSU6JRWK=
CTB-1 NWjC[Jk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M130cmlEPTB;Mj6wNlI1PiEQvF2= NEHJfFZUSU6JRWK=
MOLT-4 NWDSRWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUKwU3hVUUN3ME2yMlMzQDV|IN88US=> MknKV2FPT0WU
A101D NF7MRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfFTWM2OD1{LkO1NFEh|ryP NHzzTohUSU6JRWK=
DOHH-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPoNo9KSzVyPUKuOFIzPzlizszN NYe5W|d[W0GQR1XS
ES4 M{HMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nkXmlEPTB;Mj60N|E2PSEQvF2= NGrRepJUSU6JRWK=
SW780 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5TWM2OD1{LkWwPFg{KM7:TR?= MVjTRW5ITVJ?
VA-ES-BJ MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17iTWlEPTB;Mj61OFEyKM7:TR?= MWrTRW5ITVJ?
RPMI-8866 NGDFSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHpS4F5UUN3ME2yMlU3OjF2IN88US=> MXrTRW5ITVJ?
ML-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Prd2lEPTB;Mj61OlU4PiEQvF2= NILubYlUSU6JRWK=
MSTO-211H NFK4e3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:3TWM2OD1{LkW3OFUyKM7:TR?= M3jJbHNCVkeHUh?=
JVM-3 M4[xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLjTWM2OD1{LkW5N|I1KM7:TR?= M4rk[nNCVkeHUh?=
A3-KAW MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILudYVKSzVyPUKuOlE5OThizszN M{fRPXNCVkeHUh?=
DK-MG MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HkT2lEPTB;Mj62NlQ4OSEQvF2= MXTTRW5ITVJ?
LNCaP-Clone-FGC NFnRT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfXWoRKSzVyPUKuOlQ{OThizszN MVzTRW5ITVJ?
HT-144 NH7PSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD1{Lk[0OVc4KM7:TR?= NFLWXodUSU6JRWK=
NB69 NFX3VoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS4bJVKSzVyPUKuOlU{OzRizszN MojxV2FPT0WU
A172 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwNke1PFgh|ryP MljXV2FPT0WU
RS4-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zNXmlEPTB;Mj63NlQxPyEQvF2= NGG3VG5USU6JRWK=
DU-4475 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELtNlhKSzVyPUKuO|k2ODJizszN MVvTRW5ITVJ?
SJSA-1 NHrvN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljUTWM2OD1{LkiyOVU3KM7:TR?= M2nNNHNCVkeHUh?=
BV-173 NV\MTZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\uNGlEPTB;Mj64OFQ{QSEQvF2= MVPTRW5ITVJ?
U-2-OS NUnvOJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XO[2lEPTB;Mj65NVA4KM7:TR?= M{naRXNCVkeHUh?=
CHP-134 NFGwOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XqT2lEPTB;Mj65N|g5OiEQvF2= NH;uTo5USU6JRWK=
D-502MG MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;IT2lEPTB;Mj65O|E2PCEQvF2= MVXTRW5ITVJ?
KS-1 NFTJfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTsTWM2OD1|LkCxOlI{KM7:TR?= MlvQV2FPT0WU
A204 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTNwMEW1PFgh|ryP NHHP[WVUSU6JRWK=
KGN MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HHdGlEPTB;Mz6wPFQ6PiEQvF2= M{jrbnNCVkeHUh?=
NCI-H292 NV\IZ4N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDoTWM2OD1|LkGyNFI5KM7:TR?= NUnwTWl[W0GQR1XS
CAKI-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLPTWM2OD1|LkGyOlk1KM7:TR?= M{O4ZnNCVkeHUh?=
C2BBe1 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HWeWlEPTB;Mz6xO|AzPiEQvF2= MYTTRW5ITVJ?
NB10 NIjCNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PodmlEPTB;Mz6yNFk3PiEQvF2= NYjMS4FxW0GQR1XS
MHH-NB-11 NWPFdllsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwMk[4Nlch|ryP MWLTRW5ITVJ?
NCI-SNU-1 NFzHZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHheZdKSzVyPUOuNlc5PDNizszN NHfvcZFUSU6JRWK=
HCT-116 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkizTWM2OD1|LkOwN|M2KM7:TR?= MW\TRW5ITVJ?
G-401 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvneoJYUUN3ME2zMlM3OzJ{IN88US=> MYnTRW5ITVJ?
MN-60 M37Kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTrfZlNUUN3ME2zMlQ1ODl{IN88US=> MUDTRW5ITVJ?
SW982 NH3QbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwNUC4OFgh|ryP M1HZcHNCVkeHUh?=
RKO M4mxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCyTWM2OD1|LkWzPVM3KM7:TR?= NX7NW4hTW0GQR1XS
D-283MED NEjtWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm1UoszUUN3ME2zMlU4QTh4IN88US=> NFezb4FUSU6JRWK=
LB996-RCC M{HGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv0e2RQUUN3ME2zMlYzPTV6IN88US=> NHvpR|RUSU6JRWK=
A549 NHnGd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnIWHB1UUN3ME2zMlY{PTV{IN88US=> MXfTRW5ITVJ?
LB2241-RCC M{DYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17W[WlEPTB;Mz62OVcxQCEQvF2= NWXQclJoW0GQR1XS
SK-HEP-1 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwN{SyPVch|ryP MWjTRW5ITVJ?
G-402 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTNwOEC4N|Ih|ryP NGLWd|NUSU6JRWK=
GOTO M3;pdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrNTWM2OD1|Lki0N|M{KM7:TR?= Ml;sV2FPT0WU
LOXIMVI MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwOEW2O|Uh|ryP MlnuV2FPT0WU
NH-12 NWWwW2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\XRnd4UUN3ME20MlAyQTV7IN88US=> M3nOVnNCVkeHUh?=
CTV-1 NFPURYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMEe5O|Mh|ryP Ml\HV2FPT0WU
CP50-MEL-B M3vDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGdGlEPTB;ND6yOFM6OiEQvF2= M3LDdHNCVkeHUh?=
RH-18 NYXKZ5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTRwMke3NFYh|ryP Mn;iV2FPT0WU
NB17 NWmzV|UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInZfZRKSzVyPUSuN|E4PjhizszN NFjzc49USU6JRWK=
A375 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\OdXFmUUN3ME20MlM{PTJ2IN88US=> NXX4WnJGW0GQR1XS
IST-MES1 NFPXWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD12LkSxOFEyKM7:TR?= NVzwcItmW0GQR1XS
MZ2-MEL NVu5PYF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwNUCxOVUh|ryP NHTqc2dUSU6JRWK=
CAL-54 NH\BZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK0PWZ7UUN3ME20MlU{ODF7IN88US=> MkPvV2FPT0WU
NCI-H28 NH3oZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\zN416UUN3ME20MlYzPzF5IN88US=> MV\TRW5ITVJ?
D-247MG M1jheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrPTWM2OD12Lke1NFczKM7:TR?= M3[ycHNCVkeHUh?=
NCI-H460 NFTOTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnpRYRJUUN3ME20MlkyOTJ5IN88US=> MXHTRW5ITVJ?
MCF7 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\6[HRQUUN3ME21MlQ1OjR2IN88US=> M1fRc3NCVkeHUh?=
697 NHT1eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVwNES1OUDPxE1? M3m4UXNCVkeHUh?=
ONS-76 NH\MUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLVTWM2OD13LkW3NFA6KM7:TR?= MnLLV2FPT0WU
C32 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DxPWlEPTB;NT62NFAzQSEQvF2= NWL2doEzW0GQR1XS
OS-RC-2 NFTUWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTVwN{O4PFch|ryP MnL6V2FPT0WU
MEL-HO M3fCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSwVmtEUUN3ME21Mlg2PjZ5IN88US=> NFzDdY1USU6JRWK=
LoVo M2\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvOSmpKSzVyPU[uNFE3OjRizszN MWLTRW5ITVJ?
AGS M4j3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTZwMUS4Nlgh|ryP NIXRR3VUSU6JRWK=
GI-ME-N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1b2lEPTB;Nj6yNlQzOSEQvF2= NHXwWm9USU6JRWK=
H-EMC-SS Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTZwM{i2JO69VQ>? MmftV2FPT0WU
RVH-421 M2nQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjzTWM2OD14LkSyOFI5KM7:TR?= NIPtelRUSU6JRWK=
SW954 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jJSmlEPTB;Nj61OVU4OiEQvF2= NXL2fJN4W0GQR1XS
NB5 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jJdGlEPTB;Nj61OlE5OyEQvF2= M4rnW3NCVkeHUh?=
NCI-H2122 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr4OFVHUUN3ME22MlU5Pzl|IN88US=> NEO1OGtUSU6JRWK=
AM-38 NHLqemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDkTWM2OD14Lke1OlM6KM7:TR?= M2XZPHNCVkeHUh?=
KNS-81-FD MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q1c2lEPTB;Nj63OlQ6PCEQvF2= MlXXV2FPT0WU
LS-513 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TjVmlEPTB;Nj63PVAzPiEQvF2= NVHWOoFmW0GQR1XS
A427 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnBR|FKSzVyPU[uPFc5OjlizszN MXnTRW5ITVJ?
WM-115 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P1cGlEPTB;Nj65N|I{KM7:TR?= MlzoV2FPT0WU
COLO-829 NFPPSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTdwMkSxPFgh|ryP MYHTRW5ITVJ?
NCI-H1650 M4\DPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKwS4ZKSzVyPUeuN|kzOjhizszN NIX1OlRUSU6JRWK=
NCI-H358 NVfVeHJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrkOFNKSzVyPUeuOFQ5PzlizszN NFHQVVBUSU6JRWK=
HT-1080 M{\Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXDO|JKSzVyPUeuOFgzPTRizszN M2np[nNCVkeHUh?=
HCC2218 NUPGWWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfqXmlKSzVyPUeuOlI6PyEQvF2= MnvGV2FPT0WU
NCI-H661 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTdwOEewOlkh|ryP MWjTRW5ITVJ?
KM-H2 NF7jPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrJTWM2OD15Lki4Olk1KM7:TR?= MWDTRW5ITVJ?
RPMI-2650 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHoR4RKUUN3ME23Mlk1PDF2IN88US=> NIjFSpFUSU6JRWK=
NCI-H226 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrPeZVKSzVyPUiuNlEyOjJizszN NFH4cnNUSU6JRWK=
MKN45 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwMk[2NFIh|ryP MXjTRW5ITVJ?
D-392MG MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRThwNUK3NlIh|ryP Mo\zV2FPT0WU
RCC10RGB MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm5TWM2OD16Lki2Olk2KM7:TR?= MX\TRW5ITVJ?
CAL-51 M3XqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG1T|lKSzVyPUmuNVAzPTFizszN NViycZlXW0GQR1XS
COLO-678 M{XoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTlwM{K4NVEh|ryP NWLYZXlXW0GQR1XS
SK-MEL-24 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XjbGlEPTB;OT61OVg2PiEQvF2= NWPUfFZLW0GQR1XS
SK-MEL-30 NVuydVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTxVJJCUUN3ME25Mlk1PDd4IN88US=> M33OW3NCVkeHUh?=
MMAC-SF NUnETm91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFyLkO5OlEh|ryP M3vkcXNCVkeHUh?=
NTERA-S-cl-D1 M3niS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFyLk[1NFgh|ryP MmnqV2FPT0WU
NB12 M2iyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvxTZNKSzVyPUGxMlUxOyEQvF2= M{TVWXNCVkeHUh?=
UACC-257 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nZNGlEPTB;MUGuPFY6PSEQvF2= M{nyc3NCVkeHUh?=
LAN-6 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX2OmFKSzVyPUGxMlk6OjhizszN NX\FNXVYW0GQR1XS
SW1573 M1zibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DGfmlEPTB;MUKuN|A5PiEQvF2= Mnr5V2FPT0WU
NMC-G1 NXfSRYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF{LkSxO|Uh|ryP NHjxUXRUSU6JRWK=
SHP-77 NGPF[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof5TWM2OD1zMj61OVc1KM7:TR?= NYjkVpp6W0GQR1XS
IGROV-1 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK3TWM2OD1zMj62OVc{KM7:TR?= MYjTRW5ITVJ?
22RV1 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF{LkiwOVkh|ryP MWjTRW5ITVJ?
SK-MEL-3 MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOw[XFKSzVyPUGzMlM6PzNizszN MoLkV2FPT0WU
NCI-H1563 NHPBUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PYO2lEPTB;MUOuOFIxOiEQvF2= MnXHV2FPT0WU
IGR-1 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfOTWM2OD1zND6wN|Q4KM7:TR?= Mn32V2FPT0WU
EW-3 M3;ab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLjOpZLUUN3ME2xOE4yPjN7IN88US=> MX7TRW5ITVJ?
JEG-3 M{DaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnmNFdsUUN3ME2xOE41QTV|IN88US=> MmLRV2FPT0WU
ES3 NXnTcllIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LRU2lEPTB;MUSuOlU3OiEQvF2= NGq0cYNUSU6JRWK=
MDA-MB-175-VII Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIexWHVKSzVyPUG0MlcyOTFizszN MkjkV2FPT0WU
P30-OHK NUS0TpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;Yd2RKSzVyPUG1MlA1QTZizszN MYrTRW5ITVJ?
GP5d M3ewO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF3LkG0OlYh|ryP MX3TRW5ITVJ?
HMV-II MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XoNmlEPTB;MUWuN|M{OyEQvF2= NIq0d4FUSU6JRWK=
COLO-679 M{jFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LvN2lEPTB;MUWuOVAyKM7:TR?= MlHCV2FPT0WU
JAR MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m0RmlEPTB;MUWuO|IxPSEQvF2= M4fJXXNCVkeHUh?=
NCI-H1666 M1rjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF3LkmzPVkh|ryP M{L6b3NCVkeHUh?=
SW48 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq3S|FLUUN3ME2xOU46PTF4IN88US=> M2HWOXNCVkeHUh?=
NCI-H720 NEG1NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fDcWlEPTB;MUWuPVk5QSEQvF2= MUHTRW5ITVJ?
HT-1197 NWDBS|RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T0bGlEPTB;MU[uNFM2OiEQvF2= M3zFfXNCVkeHUh?=
HL-60 NFPYcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvoT|IxUUN3ME2xOk4xOzh2IN88US=> NImyWlhUSU6JRWK=
BEN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;pSHV7UUN3ME2xOk42PjN6IN88US=> MYjTRW5ITVJ?
HAL-01 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDt[|RKSzVyPUG2Mlg6ODlizszN NWfERXRYW0GQR1XS
SW900 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP2TWM2OD1zNj65NVMzKM7:TR?= M{XQ[HNCVkeHUh?=
SBC-1 NUjLR2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF5LkW0Nlkh|ryP NUnJcZV6W0GQR1XS
SH-4 NX21UXRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF5LkW4OFEh|ryP MXTTRW5ITVJ?
UACC-62 NH70T2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfCW2RpUUN3ME2xO{44PjN5IN88US=> Mom3V2FPT0WU
BHT-101 NU\RUYpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXURnhJUUN3ME2xPU45PzB3IN88US=> MVfTRW5ITVJ?
DB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO3eWdKSzVyPUKxMlU3PDlizszN M2\H[nNCVkeHUh?=
SK-MEL-1 NXzxOldHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJzLkW4O|Ih|ryP MkXBV2FPT0WU
NCI-H747 NYDKOmliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLIco5DUUN3ME2yNk44Ozd7IN88US=> NX3LXIx2W0GQR1XS
SK-LU-1 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWxWolVUUN3ME2yN{4{PTJ2IN88US=> MlqwV2FPT0WU
KG-1 M1LSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ|LkS5OFYh|ryP Mme0V2FPT0WU
LXF-289 M3PsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr0TWM2OD1{Mz63NVQh|ryP M4fwcnNCVkeHUh?=
HCC1954 M2rxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vkVmlEPTB;MkSuPFg1PCEQvF2= MWnTRW5ITVJ?
Ramos-2G6-4C10 NUO1T2JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH2UWtKSzVyPUK2MlQ6QDFizszN NVzxTZVJW0GQR1XS
DBTRG-05MG NGfWflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr2TWM2OD1{Nj62OFg5KM7:TR?= MnPuV2FPT0WU
NCI-H2052 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37MOGlEPTB;MkeuOVY5PCEQvF2= M3;zXnNCVkeHUh?=
RMG-I MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\wcFdbUUN3ME2yPU41OTN7IN88US=> NFjRenNUSU6JRWK=
H9 M2TzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fUUGlEPTB;M{GuN|AxQCEQvF2= MUHTRW5ITVJ?
GR-ST NVPxR2h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jEcGlEPTB;M{KuOFQ2OyEQvF2= NIHFVFlUSU6JRWK=
Mo-T MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN{LkWwOFYh|ryP MnjFV2FPT0WU
SW1088 NWe3Z25RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN{Lkm4NFEh|ryP MmizV2FPT0WU
LB2518-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTN|LkC3PVch|ryP NWjkPYFrW0GQR1XS
NCI-H82 NEfDfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3scW5sUUN3ME2zN{4yPjZzIN88US=> MmHyV2FPT0WU
LAMA-84 M4qyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTN2Lk[wO|Mh|ryP MXnTRW5ITVJ?
KYSE-450 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTN2Lk[3O|Yh|ryP MVHTRW5ITVJ?
LU-99A MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXDXotRUUN3ME2zOU4xODB5IN88US=> M{TVVXNCVkeHUh?=
BE-13 M{Dl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN3Lk[1OFUh|ryP MXrTRW5ITVJ?
GAK NWXKfmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzsTWM2OD1|NT62PVUh|ryP M3L4NHNCVkeHUh?=
NCI-H1573 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHVSFlKSzVyPUO1Mlg5OThizszN NVXPU|BXW0GQR1XS
AsPC-1 M3e1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTN4LkG1Nlch|ryP MYHTRW5ITVJ?
HDLM-2 NVH2NIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTqXVFKSzVyPUO2MlMyPiEQvF2= NVnkW2Z6W0GQR1XS
NCI-H441 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\XdWlEPTB;M{euNFY6OSEQvF2= MkP2V2FPT0WU
CAL-27 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3OTWM2OD1|Nz63NlMyKM7:TR?= M37zTHNCVkeHUh?=
OVCAR-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN7LkOxPFEh|ryP NHXVPG1USU6JRWK=
RPMI-8226 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PRRmlEPTB;M{muOVk5KM7:TR?= M2PIPHNCVkeHUh?=
EFO-21 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLKWFU2UUN3ME20NE42QDF2IN88US=> MnjpV2FPT0WU
SNU-C2B NYrmN2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HiXGlEPTB;NEGuOVA5PCEQvF2= MmDCV2FPT0WU
VM-CUB-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonNTWM2OD12Mz64NFM4KM7:TR?= Mk\jV2FPT0WU
NCI-H2087 M3Hte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD12NT6wNlM{KM7:TR?= MWXTRW5ITVJ?
EW-16 NVLhd3NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:1eGlEPTB;NE[uN|E{PyEQvF2= MVTTRW5ITVJ?
SK-N-AS MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn2[VRKSzVyPUS2MlcyPjdizszN NHHOOllUSU6JRWK=
COR-L105 NXX2VoZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL2SHdbUUN3ME20Ok45QDV5IN88US=> MWTTRW5ITVJ?
DEL M3Xq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR6LkC0Nlkh|ryP NH7NXXFUSU6JRWK=
JVM-2 M2PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR6LkC1OVgh|ryP M2nNOHNCVkeHUh?=
KARPAS-45 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLhVZM1UUN3ME20PU41PTN6IN88US=> MlHpV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL
In vivo 5% DMSO+55% PEG 300+ddH2O 8mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID